PDS Biotechnology Reports Financial Results for the Third Quarter 2020 and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
PDS Biotechnology (PDSB) Misses Q3 EPS by 3c
November 11, 2020 4:35 PM ESTPDS Biotechnology (NASDAQ: PDSB) reported Q3 EPS of ($0.23), $0.03 worse than the analyst estimate of ($0.20).
Third Quarter 2020 and Recent Business Highlights
Successfully raised approximately $19 million via a public offering of common stock.Initiated VERSATILE-002, a Phase 2 trial of PDS0101, our investigational drug candidate, in combination with standard of care KEYTRUDA® for first-line... More


